January 14, 2003

FOR: ZOLL Medical Corporation

Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832



Tuesday, January 14, 2003 – BURLINGTON, MA, – ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, and ResQSystems Inc. a manufacturer of circulatory enhancement products, today announced that the companies have formed a relationship to bring to market the ResQPOD™ Circulatory Enhancer. When used in clinical trials, this unique device has shown improved circulation and increased blood flow to vital organs during CPR (cardio pulmonary resuscitation).

In connection with the distribution agreement, ZOLL made a $1,250,000 equity investment in ResQSystems. The proceeds of this investment will be used by ResQSystems for funding additional clinical studies and supporting worldwide marketing efforts. Under the distribution agreement, ZOLL has acquired exclusive rights to distribute the ResQPOD for the cardiac resuscitation market in the U.S., Canada and Europe. The ResQPOD is CE approved for sale in Canada and Europe and distribution will begin immediately. The distribution agreement is for an initial period of five years.

Sudden cardiac arrest (SCA) affects more than 350,000 people annually in the U.S. alone and is a leading cause of death in adults worldwide. Without prompt medical attention, sudden cardiac arrest is almost always fatal. Ninety-five percent of the victims of SCA do not survive, while those who do survive often experience impaired neurological function. Maintaining adequate blood flow to vital organs is the key to patient survival and quality of life, adding valuable time to the window of opportunity for early defibrillation and advanced life support to be administered.

Clinical studies of cardiac arrest patients have shown that the ResQPOD increases the survival rate for victims of sudden cardiac arrest when used in conjunction with active compression/decompression CPR. Specifically, the ResQPOD increases blood flow to the heart and brain during CPR, which extends the window of opportunity for survival and improves the patient’s chance for complete neurological recovery. Studies are ongoing to demonstrate effectiveness during traditional CPR.

“The addition of the ResQPOD to our product line is an important step forward in helping medical personnel and trained rescuers save the lives of victims of sudden cardiac arrest,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “ResQSystems is an innovative company with a very solid foundation of clinical expertise in cardiac resuscitation. We are very optimistic about this partnership’s ability to make a significant impact on cardiac resuscitation with the introduction of the ResQPOD technology.”

Mr. Packer added, “This gives us an additional complementary product in our portfolio and allows us to capitalize on our existing relationships. It also gives us the opportunity to establish relationships with competitive defibrillator accounts. Our plan is to sell in Western Europe and Canada now and expand distribution to the United States upon receipt of 510k marketing clearance, which is targeted for early 2004.”

“ZOLL has long been recognized as the technical leader in devices that have revolutionized the field of cardiac resuscitation, in both the pre-hospital and hospital markets. ZOLL’s acceptance of the ResQPOD is an important endorsement of our technology,” said Keith G. Lurie, M.D., Founder and Chief Executive of ResQSystems. “Their commitment and innovation is noteworthy and our partnership with ZOLL will help ensure our new technology gets to patients in cardiac arrest. Lives will be saved as a result.”

Dr. Lurie serves as Associate Professor of Medicine at the University of Minnesota. A graduate of Yale University and Stanford University School of Medicine, Dr. Lurie also serves as a member of the AHA Emergency Cardiovascular Care Subcommittee.

About ResQSystems

ResQSystems Inc., headquartered in Eden Prairie, MN is a medical device company that designs and manufactures products, which enhance blood flow to the vital organs including the heart and the brain. The company’s products are used when an increase in circulation or blood flow is indicated. ResQSystems’ technology is embodied into simple devices that can be used by virtually anyone, from the layperson to the trained professional, and in any setting including the home to the hospital. ResQSystems’ products will become available for sale in Europe in early 2003. For information regarding the company and its products, visit the ResQSystems Inc. website at www.ResQSystems.com.

About ZOLL Medical Corporation

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive cardiac resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit the ZOLL web site at www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, the intent, belief or current expectations of ZOLL, its directors or its officers, primarily with respect to ZOLL’s business model and future operating performance of ZOLL, including the use of funds by ResQSystems, the impact of ResQPOD technology on cardiac resuscitation, ZOLL’s ability to capitalize on existing relationships and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in ZOLL’s Annual Report on Form 10-K filed on December 30, 2002, uncertainties regarding the market, acceptance and profitability of the ResQPOD™ Circulatory Enhancer, the timing and ability to obtain 510K clearance for the ResQPOD and the on-going budgeting problems for many state and local governments.